Tocilizumab Patent Expiration
Tocilizumab Large Molecule Patents
Given below is the list of large molecule patents protecting Tocilizumab, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Actemra | USUS8568720 | High concentration antibody-containing liquid formulation | Nov 05, 2029 | Genentech, Inc. |
| Actemra | USUS7521052 | Methods for treating interleukin-6 related diseases |
Apr 28, 2024
(Expired) | Genentech, Inc. |
| Actemra | USUS11667720 | Subcutaneously administered anti-IL-6 receptor antibody | Nov 07, 2031 | Genentech, Inc. |
| Actemra | USUS11008394 | High concentration antibody-containing liquid formulation | Dec 26, 2028 | Genentech, Inc. |
| Actemra | USUS11136610 | Method for the production of a glycosylated immunoglobulin | Oct 25, 2030 | Genentech, Inc. |
| Actemra | USUS8709409 | Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate |
Jun 22, 2024
(Expired) | Genentech, Inc. |
| Actemra | USUS9750752 | Subcutaneously administered anti-IL-6 receptor antibody | Aug 30, 2032 | Genentech, Inc. |
| Actemra | USUS10662237 | Method to improve virus filtration capacity | Aug 07, 2031 | Genentech, Inc. |
| Actemra | USUS10829732 | Cell culture compositions with antioxidants and methods for polypeptide production | Mar 14, 2034 | Genentech, Inc. |
| Actemra | USUS11359026 | High concentration antibody-containing liquid formulation | Dec 26, 2028 | Genentech, Inc. |
| Actemra | USUS11021728 | Method for the production of a glycosylated immunoglobulin | Oct 25, 2030 | Genentech, Inc. |
| Actemra | USUS10231981 | Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis | Dec 03, 2031 | Genentech, Inc. |
| Actemra | USUS10590164 | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration | Mar 19, 2033 | Genentech, Inc. |
| Actemra | USUS8580264 | Subcutaneously administered anti-IL-6 receptor antibody | Nov 07, 2031 | Genentech, Inc. |
| Actemra | USUS10744201 | Method for treating rheumatoid arthritis with a human IL-6 receptor antibody and methotrexate |
Apr 28, 2024
(Expired) | Genentech, Inc. |
| Actemra | USUS7332289 | Method of purifying protein |
Aug 04, 2023
(Expired) | Genentech, Inc. |
| Actemra | USUS10336983 | Method for increasing the specific production rate of eukaryotic cells | Jul 31, 2035 | Genentech, Inc. |
| Actemra | USUS10874677 | Subcutaneously administered anti-IL-6 receptor antibody | Mar 02, 2032 | Genentech, Inc. |
| Actemra | USUS10982003 | Production of proteins in glutamine-free cell culture media | Aug 06, 2030 | Genentech, Inc. |
| Actemra | USUS10017732 | Cell culture compositions with antioxidants and methods for polypeptide production | Dec 25, 2034 | Genentech, Inc. |
| Actemra | USUS8574869 | Prevention of disulfide bond reduction during recombinant production of polypeptides | Jul 08, 2028 | Genentech, Inc. |
| Actemra | USUS11078294 | Prevention of disulfide bond reduction during recombinant production of polypeptides | Jul 08, 2028 | Genentech, Inc. |
| Actemra | USUS8512983 | Production of proteins in glutamine-free cell culture media | Jan 04, 2031 | Genentech, Inc. |
| Actemra | USUS10676710 | Cell culture compositions with antioxidants and methods for polypeptide production | Mar 14, 2034 | Genentech, Inc. |
| Actemra | USUS8617550 | Treatment of vasculitis with IL-6 antagonist | Mar 03, 2026 | Genentech, Inc. |
| Actemra | USUS9714293 | Production of proteins in glutamine-free cell culture media | Aug 06, 2030 | Genentech, Inc. |
| Actemra | USUS11584798 | High concentration antibody-containing liquid formulation | Dec 26, 2028 | Genentech, Inc. |
| Actemra | USUS11377678 | Method for the production of a glycosylated immunoglobulin | Oct 25, 2030 | Genentech, Inc. |
| Actemra | USUS9539263 | Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis | May 23, 2032 | Genentech, Inc. |
| Actemra | USUS8398980 | Subtypes of humanized antibody against interleukin-6 receptor | Feb 25, 2028 | Genentech, Inc. |
| Actemra | USUS9902777 | Methods for producing subtypes of humanized antibody against interleukin-6 receptor | May 28, 2025 | Genentech, Inc. |
| Actemra | USUS10501769 | Method for the production of a glycosylated immunoglobulin | Oct 25, 2030 | Genentech, Inc. |
| Actemra | USUS11136375 | Method for production of antibody | Jul 19, 2029 | Genentech, Inc. |
| Actemra | USUS8734800 | Subtypes of humanized antibody against interleukin-6 receptor | Mar 24, 2025 | Genentech, Inc. |
| Actemra | USUS9630988 | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration | Jun 13, 2033 | Genentech, Inc. |
Tocilizumab's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List